The prevalence—proportion of cases—of hypertension in minors has almost doubled worldwide between 2000 and 2020, rising from 3.4% to 6.53% in boys and slightly less in girls, according to a systematic review published in The Lancet Child & Adolescent Health. The study brings together data from nearly 444,000 children and adolescents up to the age of 19 in 21 countries.
The Pfizer-BioNTech COVID-19 vaccine has been linked to rare cases of heart inflammation in children and young people. The largest study of these risks in children, published in The Lancet Child & Adolescent Health, concluded that receiving the vaccine is associated with a risk of developing myocarditis or pericarditis within six months of 0.85 additional cases per 100,000 vaccinated children; while after COVID-19 infection, the risk is 2.24 additional cases per 100,000. The study used data from 98% of the British population under the age of 18 (almost 14 million) between January 2020 and December 2022.
Childhood vaccination rates have increased modestly worldwide in 2024, without reaching their pre-COVID-19 pandemic levels, according to data from the WHO and UNICEF. For example, global measles vaccination coverage rose by one percentage point from the previous year, reaching 84% of girls and boys who had received one dose in 2024, compared to 86% in 2019.
Between 1980 and 2023, childhood vaccination rates against diphtheria, tetanus, whooping cough, measles, polio and tuberculosis doubled worldwide, according to a study published in The Lancet. However, this increase slowed in many countries between 2010 and 2019; during this period, measles vaccination declined in half of all countries.
So-called precision oncology involves the use of drugs that target specific molecular alterations in the tumour. These therapies are usually tested in clinical trials in adults and most have not been approved for use in children. An opinion article calls for these trials to be extended to children as well, given the difficulty of conducting such trials in children due to the small number of cases. According to the authors, who publish the text in the journal Trends in Cancer, given that children and adolescents tend to tolerate therapy better than older adults, ‘the time has come to consider age-agnostic approvals, i.e. approvals that include children and adults of any age’.
Genome analysis of 11,555 individuals revealed 60 genes involved in congenital heart disease, according to a study published today in the journal PNAS. Congenital heart disease is one of the most common birth defects and affects between 1 and 1.8% of live births.
In the context of World AIDS Day, which is celebrated on 1 December, it is essential to reflect on one of the most urgent challenges in the fight against this disease: HIV in the paediatric population. A project led by the Complutense University of Madrid seeks to reduce paediatric mortality by training research leaders in sub-Saharan Africa and applying technology and innovation.
The relative risk of being born with a major heart defect is 36% in babies conceived using assisted reproductive techniques, such as in vitro fertilisation, compared to newborns not using these techniques, according to a study published in the European Heart Journal. The absolute risk was 1.84% versus 1.15%. The research, which included more than seven million babies born in Denmark, Finland, Norway and Sweden, also shows that the increased risk is especially associated with multiple births, which are more common in assisted reproduction.
A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.
A case-control study published in JAMA Pediatrics reports a relationship between certain aberrant metabolic biomarkers at birth and sudden infant death syndrome (SIDS). Although the research is preliminary and no screening test for this syndrome is yet available, the researchers believe their study is an important step toward integrating metabolic and genetic markers to identify infants at higher risk of sudden death.